

# Beom Kyung Kim

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4963616/publications.pdf>

Version: 2024-02-01

252  
papers

5,992  
citations

87843

38  
h-index

123376

61  
g-index

261  
all docs

261  
docs citations

261  
times ranked

6340  
citing authors

#	ARTICLE	IF	CITATIONS
1	Validation of FIB-4 and comparison with other simple noninvasive indices for predicting liver fibrosis and cirrhosis in hepatitis B virus-infected patients. <i>Liver International</i> , 2010, 30, 546-553.	1.9	225
2	A Liver Stiffness Measurement-Based, Noninvasive Prediction Model for High-Risk Esophageal Varices in B-Viral Liver Cirrhosis. <i>American Journal of Gastroenterology</i> , 2010, 105, 1382-1390.	0.2	194
3	Complete response at first chemoembolization is still the most robust predictor for favorable outcome in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2015, 62, 1304-1310.	1.8	148
4	HBV Genotypes: Relevance to Natural History, Pathogenesis and Treatment of Chronic Hepatitis B. <i>Antiviral Therapy</i> , 2011, 16, 1169-1186.	0.6	146
5	A multicenter study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in South Korea. <i>Journal of Hepatology</i> , 2019, 71, 456-464.	1.8	131
6	Increased risk of hepatocellular carcinoma in chronic hepatitis B patients with transient elastography-defined subclinical cirrhosis. <i>Hepatology</i> , 2015, 61, 1851-1859.	3.6	121
7	Prediction of Development of Liver-Related Events by Transient Elastography in Hepatitis B Patients With Complete Virological Response on Antiviral Therapy. <i>American Journal of Gastroenterology</i> , 2014, 109, 1241-1249.	0.2	120
8	Persistent hepatitis B viral replication affects recurrence of hepatocellular carcinoma after curative resection. <i>Liver International</i> , 2008, 28, 393-401.	1.9	113
9	Prediction of microvascular invasion before curative resection of hepatocellular carcinoma. <i>Journal of Surgical Oncology</i> , 2008, 97, 246-252.	0.8	104
10	Validation of hepatitis B virus-related hepatocellular carcinoma prediction models in the era of antiviral therapy. <i>Hepatology</i> , 2015, 62, 1757-1766.	3.6	97
11	Noninvasive models to predict liver cirrhosis in patients with chronic hepatitis B. <i>Liver International</i> , 2007, 27, 969-976.	1.9	96
12	Applicability of BCLC stage for prognostic stratification in comparison with other staging systems: single centre experience from long-term clinical outcomes of 1717 treatment-naïve patients with hepatocellular carcinoma. <i>Liver International</i> , 2012, 32, 1120-1127.	1.9	91
13	Radiological response predicts survival following transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 1343-1350.	1.9	83
14	Clinical outcomes and predictors for relapse after cessation of oral antiviral treatment in chronic hepatitis B patients. <i>Journal of Gastroenterology</i> , 2016, 51, 830-839.	2.3	78
15	What are "true normal" liver stiffness values using FibroScan <sup>®</sup> : a prospective study in healthy living liver and kidney donors in South Korea. <i>Liver International</i> , 2010, 30, 268-274.	1.9	76
16	Addition of tumor multiplicity improves the prognostic performance of the hepatoma arterial embolization prognostic score. <i>Liver International</i> , 2016, 36, 100-107.	1.9	76
17	Prospective comparison of prognostic values of modified Response Evaluation Criteria in Solid Tumours with European Association for the Study of the Liver criteria in hepatocellular carcinoma following chemoembolisation. <i>European Journal of Cancer</i> , 2013, 49, 826-834.	1.3	71
18	Combined use of AFP, PIVKA-II, and AFP-L3 as tumor markers enhances diagnostic accuracy for hepatocellular carcinoma in cirrhotic patients. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 344-353.	0.6	68

#	ARTICLE	IF	CITATIONS
19	Nonalcoholic Fatty Liver Disease and Sarcopenia Are Independently Associated With Cardiovascular Risk. <i>American Journal of Gastroenterology</i> , 2020, 115, 584-595.	0.2	68
20	Clinical application of liver stiffness measurement using transient elastography in chronic liver disease from longitudinal perspectives. <i>World Journal of Gastroenterology</i> , 2013, 19, 1890.	1.4	67
21	Risk prediction for patients with hepatocellular carcinoma undergoing chemoembolization: development of a prediction model. <i>Liver International</i> , 2016, 36, 92-99.	1.9	64
22	Prospective Validation of ELF Test in Comparison with Fibroscan and FibroTest to Predict Liver Fibrosis in Asian Subjects with Chronic Hepatitis B. <i>PLoS ONE</i> , 2012, 7, e41964.	1.1	64
23	Prognostic value of the 7th edition of the AJCC staging system as a clinical staging system in patients with hepatocellular carcinoma. <i>European Journal of Cancer</i> , 2011, 47, 2568-2575.	1.3	59
24	Long-term clinical outcomes of hepatic arterial infusion chemotherapy with cisplatin with or without 5-fluorouracil in locally advanced hepatocellular carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2011, 137, 659-667.	1.2	57
25	Risk Assessment of Esophageal Variceal Bleeding in B-Viral Liver Cirrhosis by a Liver Stiffness Measurement-Based Model. <i>American Journal of Gastroenterology</i> , 2011, 106, 1654-1662.	0.2	56
26	Early $\alpha$ -fetoprotein response as a predictor for clinical outcome after localized concurrent chemoradiotherapy for advanced hepatocellular carcinoma. <i>Liver International</i> , 2011, 31, 369-376.	1.9	55
27	Surgical Resection After Down-Staging of Locally Advanced Hepatocellular Carcinoma by Localized Concurrent Chemoradiotherapy. <i>Annals of Surgical Oncology</i> , 2014, 21, 3646-3653.	0.7	53
28	Evolution from WHO to EASL and mRECIST for hepatocellular carcinoma: considerations for tumor response assessment. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 335-348.	1.4	51
29	Liver fibrosis assessed with transient elastography is an independent risk factor for ischemic stroke. <i>Atherosclerosis</i> , 2017, 260, 156-162.	0.4	49
30	Factors associated with significant liver fibrosis assessed using transient elastography in general population. <i>World Journal of Gastroenterology</i> , 2015, 21, 1158.	1.4	48
31	<sup>18</sup> F-fluorodeoxyglucose uptake on positron emission tomography as a prognostic predictor in locally advanced hepatocellular carcinoma. <i>Cancer</i> , 2011, 117, 4779-4787.	2.0	47
32	Hepatocellular carcinoma in patients with chronic hepatitis C virus infection in the Asia-Pacific region. <i>Journal of Gastroenterology</i> , 2013, 48, 681-688.	2.3	47
33	Leflunomide increases the risk of silent liver fibrosis in patients with rheumatoid arthritis receiving methotrexate. <i>Arthritis Research and Therapy</i> , 2012, 14, R232.	1.6	45
34	Prospective Validation of FibroTest in Comparison with Liver Stiffness for Predicting Liver Fibrosis in Asian Subjects with Chronic Hepatitis B. <i>PLoS ONE</i> , 2012, 7, e35825.	1.1	45
35	Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune-tolerant phase. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 196-204.	1.9	43
36	Gastrointestinal Complications After Concurrent Chemoradiation Therapy in Patients With Hepatocellular Carcinoma: Endoscopic Findings and Risk Factors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, 1343-1351.	0.4	42

#	ARTICLE	IF	CITATIONS
37	Prevention of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Virus Infection. <i>Oncology</i> , 2011, 81, 41-49.	0.9	42
38	Improvement of Liver Fibrosis after Long-Term Antiviral Therapy Assessed by Fibroscan in Chronic Hepatitis B Patients With Advanced Fibrosis. <i>American Journal of Gastroenterology</i> , 2017, 112, 882-891.	0.2	42
39	Number of Target Lesions for EASL and Modified RECIST to Predict Survivals in Hepatocellular Carcinoma Treated with Chemoembolization. <i>Clinical Cancer Research</i> , 2013, 19, 1503-1511.	3.2	38
40	Risk assessment of clinical outcomes in Asian patients with chronic hepatitis B using enhanced liver fibrosis test. <i>Hepatology</i> , 2014, 60, 1911-1919.	3.6	37
41	Validation of PAGE-B model in Asian chronic hepatitis B patients receiving entecavir or tenofovir. <i>Liver International</i> , 2017, 37, 1788-1795.	1.9	37
42	<i>Wisteria floribunda</i> agglutinin-positive human Mac-2 binding protein predicts the risk of HBV-related liver cancer development. <i>Liver International</i> , 2017, 37, 879-887.	1.9	37
43	Gamma-glutamyl transpeptidase-to-platelet ratio is an independent predictor of hepatitis B virus-related liver cancer. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1221-1229.	1.4	37
44	Sarcopenia is associated with the risk of significant liver fibrosis in metabolically unhealthy subjects with chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 300-312.	1.9	37
45	Development of a New Nomogram Including Neutrophil-to-Lymphocyte Ratio to Predict Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. <i>Cancers</i> , 2019, 11, 509.	1.7	37
46	Cardiovascular Risk Is Elevated in Lean Subjects with Nonalcoholic Fatty Liver Disease. <i>Gut and Liver</i> , 2022, 16, 290-299.	1.4	37
47	Conventional versus drug-eluting beads chemoembolization for hepatocellular carcinoma: Emphasis on the impact of tumor size. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 487-496.	1.4	36
48	Atezolizumab/Bevacizumab vs. Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Real-World, Multi-Center Study. <i>Cancers</i> , 2022, 14, 1747.	1.7	36
49	Liver stiffness-based model for prediction of hepatocellular carcinoma in chronic hepatitis B virus infection: comparison with histological fibrosis. <i>Liver International</i> , 2015, 35, 1054-1062.	1.9	34
50	Lower Incidence of Hepatocellular Carcinoma and Cirrhosis in Hepatitis C Patients with Sustained Virological Response by Pegylated Interferon and Ribavirin. <i>Digestive Diseases and Sciences</i> , 2015, 60, 573-581.	1.1	34
51	Serum Dickkopf-1 as a Biomarker for the Diagnosis of Hepatocellular Carcinoma. <i>Yonsei Medical Journal</i> , 2015, 56, 1296.	0.9	33
52	Factors Affecting the Accuracy of Controlled Attenuation Parameter (CAP) in Assessing Hepatic Steatosis in Patients with Chronic Liver Disease. <i>PLoS ONE</i> , 2014, 9, e98689.	1.1	33
53	Long-term changes of liver stiffness values assessed using transient elastography in patients with chronic hepatitis B receiving entecavir. <i>Liver International</i> , 2014, 34, 1216-1223.	1.9	32
54	A Novel Model to Predict Esophageal Varices in Patients with Compensated Cirrhosis Using Acoustic Radiation Force Impulse Elastography. <i>PLoS ONE</i> , 2015, 10, e0121009.	1.1	32

#	ARTICLE	IF	CITATIONS
55	Association Between Level of Fibrosis, Rather Than Antiviral Regimen, and Outcomes of Patients With Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1647-1656.e6.	2.4	32
56	Liver Fibrosis, Not Steatosis, Associates with Long-Term Outcomes in Ischaemic Stroke Patients. <i>Cerebrovascular Diseases</i> , 2019, 47, 32-39.	0.8	32
57	A novel liver stiffness measurement-based prediction model for cirrhosis in hepatitis B patients. <i>Liver International</i> , 2010, 30, 1073-1081.	1.9	31
58	The risk of hepatocellular carcinoma among chronic hepatitis B virus-infected patients outside current treatment criteria. <i>Journal of Viral Hepatitis</i> , 2019, 26, 1465-1472.	1.0	31
59	Influence of hepatic steatosis on the outcomes of patients with chronic hepatitis B treated with entecavir and tenofovir. <i>Clinical and Molecular Hepatology</i> , 2019, 25, 283-293.	4.5	31
60	A survey on transarterial chemoembolization refractoriness and a real-world treatment pattern for hepatocellular carcinoma in Korea. <i>Clinical and Molecular Hepatology</i> , 2020, 26, 24-32.	4.5	31
61	Hepatocellular Carcinoma Risk Steadily Persists over Time Despite Long-Term Antiviral Therapy for Hepatitis B: A Multicenter Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 832-837.	1.1	30
62	Normal liver stiffness values differ between men and women: A prospective study for healthy living liver and kidney donors in a native Korean population. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 781-788.	1.4	29
63	Red cell volume distribution width to platelet ratio in assessment of liver fibrosis in patients with chronic hepatitis B. <i>Liver International</i> , 2016, 36, 24-30.	1.9	29
64	External validation of the modified PAGE-B score in Asian chronic hepatitis B patients receiving antiviral therapy. <i>Liver International</i> , 2019, 39, 1624-1630.	1.9	29
65	Early on-treatment change in liver stiffness predicts development of liver-related events in chronic hepatitis B patients receiving antiviral therapy. <i>Liver International</i> , 2013, 33, 180-189.	1.9	28
66	Hepatic fibrosis assessed using transient elastography independently associated with coronary artery calcification. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1536-1542.	1.4	28
67	Use of Wisteria Floribunda Agglutinin-Positive Human Mac-2 Binding Protein in Assessing Risk of Hepatocellular Carcinoma Due to Hepatitis B Virus. <i>Medicine (United States)</i> , 2016, 95, e3328.	0.4	28
68	Risk stratification using sarcopenia status among subjects with metabolic dysfunction-associated fatty liver disease. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2021, 12, 1168-1178.	2.9	28
69	A single institutional experience of surgically resected thymic epithelial tumors over 10 years: clinical outcomes and clinicopathologic features. <i>Oncology Reports</i> , 2008, 19, 1525-31.	1.2	27
70	Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy: A Korean multicenter study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1463-1469.	1.4	26
71	Prognosis of hepatocellular carcinoma patients with extrahepatic metastasis and the controllability of intrahepatic lesions. <i>Clinical and Experimental Metastasis</i> , 2014, 31, 475-482.	1.7	26
72	The efficacies of entecavir and tenofovir in terms of enhancing prognosis after curative treatment of hepatitis B virus-related hepatocellular carcinoma. <i>European Journal of Internal Medicine</i> , 2021, 89, 48-55.	1.0	26

#	ARTICLE	IF	CITATIONS
73	UNOS Down-Staging Criteria for Liver Transplantation of Hepatocellular Carcinoma: Systematic Review and Meta-Analysis of 25 Studies. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 1475-1484.	2.4	26
74	Use of the Delta Neutrophil Index as a Prognostic Factor of Mortality in Patients with Spontaneous Bacterial Peritonitis: Implications of a Simple and Useful Marker. <i>PLoS ONE</i> , 2014, 9, e86884.	1.1	25
75	Relationship between Cerebral Microbleeds and Liver Stiffness Determined by Transient Elastography. <i>PLoS ONE</i> , 2015, 10, e0139227.	1.1	25
76	Development and validation of a prognostic model for patients with hepatocellular carcinoma undergoing radiofrequency ablation. <i>Cancer Medicine</i> , 2019, 8, 5023-5032.	1.3	25
77	Liver Stiffness Value-Based Risk Estimation of Late Recurrence after Curative Resection of Hepatocellular Carcinoma: Development and Validation of a Predictive Model. <i>PLoS ONE</i> , 2014, 9, e99167.	1.1	24
78	Early $\alpha$ -fetoprotein response predicts survival in patients with advanced hepatocellular carcinoma treated with sorafenib. <i>Journal of Hepatocellular Carcinoma</i> , 2015, 2, 39.	1.8	24
79	Effects of Entecavir and Tenofovir on Renal Function in Patients with Hepatitis B Virus-Related Compensated and Decompensated Cirrhosis. <i>Gut and Liver</i> , 2017, 11, 828-834.	1.4	24
80	Validation of the CAMD Score in Patients With Chronic Hepatitis B Virus Infection Receiving Antiviral Therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 693-699.e1.	2.4	24
81	Liver resection versus liver transplantation for hepatocellular carcinoma within Milan criteria: a meta-analysis of 18,421 patients. <i>Hepatobiliary Surgery and Nutrition</i> , 2022, 11, 78-93.	0.7	24
82	Subcirrhotic liver stiffness by FibroScan correlates with lower risk of hepatocellular carcinoma in patients with HBV-related cirrhosis. <i>Hepatology International</i> , 2017, 11, 268-276.	1.9	23
83	Tenofovir versus tenofovir plus entecavir for chronic hepatitis B with lamivudine resistance and entecavir resistance. <i>Journal of Viral Hepatitis</i> , 2017, 24, 141-147.	1.0	23
84	An optimized hepatocellular carcinoma prediction model for chronic hepatitis B with well-controlled viremia. <i>Liver International</i> , 2020, 40, 1736-1743.	1.9	23
85	Use of transient elastography to predict de novo recurrence after radiofrequency ablation for hepatocellular carcinoma. <i>OncoTargets and Therapy</i> , 2015, 8, 347.	1.0	22
86	Prognostic role of magnetic resonance imaging vs. computed tomography for hepatocellular carcinoma undergoing chemoembolization. <i>Liver International</i> , 2015, 35, 1722-1730.	1.9	22
87	Feasibility of dynamic risk prediction for hepatocellular carcinoma development in patients with chronic hepatitis B. <i>Liver International</i> , 2018, 38, 676-686.	1.9	22
88	Lenvatinib is independently associated with the reduced risk of progressive disease when compared with sorafenib in patients with advanced hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 1317-1325.	1.4	22
89	Hepatic Steatosis Index in the Detection of Fatty Liver in Patients with Chronic Hepatitis B Receiving Antiviral Therapy. <i>Gut and Liver</i> , 2021, 15, 117-127.	1.4	22
90	Dickkopf-1 induces angiogenesis via VEGF receptor 2 regulation independent of the Wnt signaling pathway. <i>Oncotarget</i> , 2017, 8, 58974-58984.	0.8	22

#	ARTICLE	IF	CITATIONS
91	Subclassification of Barcelona Clinic Liver Cancer B and C hepatocellular carcinoma: A cohort study of the multicenter registry database. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 842-847.	1.4	21
92	Prognosis of Early-Stage Hepatocellular Carcinoma: Comparison between Trans-Arterial Chemoembolization and Radiofrequency Ablation. <i>Cancers</i> , 2020, 12, 2527.	1.7	21
93	Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir Treatment for Chronic Hepatitis B Virus. <i>JAMA Network Open</i> , 2022, 5, e2219407.	2.8	21
94	Risk Assessment of Development of Hepatic Decompensation in Histologically Proven Hepatitis B Viral Cirrhosis Using Liver Stiffness Measurement. <i>Digestion</i> , 2012, 85, 219-227.	1.2	20
95	Efficacy of Sorafenib Monotherapy versus Sorafenib-Based Loco-Regional Treatments in Advanced Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2013, 8, e77240.	1.1	20
96	Comparison between chronic hepatitis B patients with untreated immune-tolerant phase vs. those with virological response by antivirals. <i>Scientific Reports</i> , 2019, 9, 2508.	1.6	20
97	Serum <i>Wisteria floribunda</i> agglutinin-positive human Mac-2 binding protein level predicts recurrence of hepatitis B virus-related hepatocellular carcinoma after curative resection. <i>Clinical and Molecular Hepatology</i> , 2020, 26, 33-44.	4.5	20
98	Risk assessment of hepatocellular carcinoma development for indeterminate hepatic nodules in patients with chronic hepatitis B. <i>Clinical and Molecular Hepatology</i> , 2019, 25, 390-399.	4.5	20
99	The Modified Response Evaluation Criteria in Solid Tumors (RECIST) Yield a More Accurate Prognoses Than the RECIST 1.1 in Hepatocellular Carcinoma Treated with Transarterial Radioembolization. <i>Gut and Liver</i> , 2020, 14, 765-774.	1.4	20
100	Long-term clinical outcomes of self-expanding metal stents for treatment of malignant gastroesophageal junction obstructions and prognostic factors for stent patency: Effects of anticancer treatments. <i>Digestive and Liver Disease</i> , 2010, 42, 436-440.	0.4	19
101	Clinical Application of Liver Stiffness Measurement Using Transient Elastography: A Surgical Perspective. <i>Digestion</i> , 2013, 88, 258-265.	1.2	19
102	Efficacy and Safety of Liver-Directed Concurrent Chemoradiotherapy and Sequential Sorafenib for Advanced Hepatocellular Carcinoma: A Prospective Phase 2 Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 106-115.	0.4	19
103	Negligible risks of hepatocellular carcinoma during biomarker-defined immune-tolerant phase for patients with chronic hepatitis B. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 295-304.	4.5	19
104	Current status of and strategies for hepatitis C control in South Korea. <i>Clinical and Molecular Hepatology</i> , 2017, 23, 212-218.	4.5	19
105	Sarcopenia Is Independently Associated with the Degree of Liver Fibrosis in Patients with Type 2 Diabetes Mellitus. <i>Gut and Liver</i> , 2020, 14, 626-635.	1.4	19
106	Prognostic value of the combined use of transient elastography and fibrotest in patients with chronic hepatitis B. <i>Liver International</i> , 2015, 35, 455-462.	1.9	18
107	Prevalence and Predictors of Significant Fibrosis Among Subjects with Transient Elastography-Defined Nonalcoholic Fatty Liver Disease. <i>Digestive Diseases and Sciences</i> , 2017, 62, 2150-2158.	1.1	18
108	Using transient elastography to predict hepatocellular carcinoma recurrence after radiofrequency ablation. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1079-1086.	1.4	18

#	ARTICLE	IF	CITATIONS
109	Hepatic Decompensation in Cirrhotic Patients Receiving Antiviral Therapy for Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1950-1958.e7.	2.4	18
110	Advanced Liver Fibrosis Predicts Unfavorable Long-Term Prognosis in First-Ever Ischemic Stroke or Transient Ischemic Attack. <i>Cerebrovascular Diseases</i> , 2020, 49, 474-480.	0.8	18
111	Impact of tenofovir alafenamide vs. entecavir on hepatocellular carcinoma risk in patients with chronic hepatitis B. <i>Hepatology International</i> , 2021, 15, 1083-1092.	1.9	18
112	Substitution at rt269 in Hepatitis B Virus Polymerase Is a Compensatory Mutation Associated with Multi-Drug Resistance. <i>PLoS ONE</i> , 2015, 10, e0136728.	1.1	18
113	Progression of Untreated Minimally Active Chronic HBV Infection Compared to Inactive Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2808-2810.e2.	2.4	17
114	Prognosis of Untreated Minimally Active Chronic Hepatitis B Patients in Comparison With Virological Responders by Antivirals. <i>Clinical and Translational Gastroenterology</i> , 2019, 10, e00036.	1.3	17
115	Fibrosis-4 index at diagnosis can predict all-cause mortality in patients with rheumatoid arthritis: A retrospective monocentric study. <i>Modern Rheumatology</i> , 2020, 30, 70-77.	0.9	17
116	Factors Influencing the Diagnostic Accuracy of Acoustic Radiation Force Impulse Elastography in Patients with Chronic Hepatitis B. <i>Gut and Liver</i> , 2016, 10, 275.	1.4	17
117	Prospective validation of P2/MS noninvasive index using complete blood counts for detecting oesophageal varices in B-viral cirrhosis. <i>Liver International</i> , 2010, 30, 860-866.	1.9	16
118	Long-term outcomes of chronic hepatitis B virus infection in the era of antiviral therapy in Korea. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1005-1011.	1.4	16
119	Reproducibility of European Association for the Study of the Liver criteria and modified Response Evaluation Criteria in Solid Tumors in patients treated with sorafenib. <i>Liver International</i> , 2018, 38, 1655-1663.	1.9	16
120	Predicting Liver-Related Events Using Transient Elastography in Chronic Hepatitis C Patients with Sustained Virological Response. <i>Gut and Liver</i> , 2016, 10, 429-36.	1.4	16
121	Transarterial Radioembolization Versus Concurrent Chemoradiation Therapy for Locally Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 396-406.	0.4	15
122	Alpha-Fetoprotein, Des-Gamma-Carboxy Prothrombin, and Modified RECIST Response as Predictors of Survival after Transarterial Radioembolization for Hepatocellular Carcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 2019, 30, 1194-1200.e1.	0.2	15
123	Controlled attenuation parameter value and the risk of hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy. <i>Hepatology International</i> , 2021, 15, 892-900.	1.9	15
124	Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1570-1578.	1.0	15
125	Normal enhanced liver fibrosis (ELF) values in apparently healthy subjects undergoing a health checkup and in living liver donors in South Korea. <i>Liver International</i> , 2013, 33, 706-713.	1.9	14
126	Normal Controlled Attenuation Parameter Values: A Prospective Study of Healthy Subjects Undergoing Health Checkups and Liver Donors in Korea. <i>Digestive Diseases and Sciences</i> , 2015, 60, 234-242.	1.1	14



#	ARTICLE	IF	CITATIONS
127	Transient Elastography is Superior to FIB-4 in Assessing the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B. <i>Medicine (United States)</i> , 2016, 95, e3434.	0.4	14
128	Incidence and risk factors of delayed postpolypectomy bleeding in patients with chronic liver disease. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 618-624.	0.6	14
129	Predictors of failure to detect early hepatocellular carcinoma in patients with chronic hepatitis B who received regular surveillance. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1201-1212.	1.9	14
130	Changes in real-life practice for hepatocellular carcinoma patients in the Republic of Korea over a 12-year period: A nationwide random sample study. <i>PLoS ONE</i> , 2019, 14, e0223678.	1.1	14
131	Paper Alert. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 1295-1298.	0.8	14
132	Fibrotic Burden Determines Cardiovascular Risk among Subjects with Metabolic Dysfunction-Associated Fatty Liver Disease. <i>Gut and Liver</i> , 2022, 16, 786-797.	1.4	14
133	Longitudinal assessment of alpha-fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 1283-1290.	0.6	13
134	An observational study on long-term renal outcome in patients with chronic hepatitis B treated with tenofovir disoproxil fumarate. <i>Journal of Viral Hepatitis</i> , 2020, 27, 316-322.	1.0	13
135	Natural History of Untreated HBeAg-Positive Chronic HBV Infection With Persistently Elevated HBV DNA but Normal Alanine Aminotransferase. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00140.	1.3	13
136	Antiviral efficacies of currently available rescue therapies for multidrug-resistant chronic hepatitis B. <i>Clinical and Molecular Hepatology</i> , 2013, 19, 29.	4.5	13
137	Long-term Efficacy of Tenofovir Disoproxil Fumarate Monotherapy for Multidrug-Resistant Chronic HBV infection. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1348-1355.e2.	2.4	12
138	Negligible HCC risk during stringently defined untreated immune-tolerant phase of chronic hepatitis B. <i>European Journal of Internal Medicine</i> , 2021, 84, 68-73.	1.0	12
139	Predictive Performance of CAGE-B and SAGE-B Models in Asian Treatment-Naive Patients Who Started Entecavir for Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e794-e807.	2.4	12
140	Association between the severity of liver fibrosis and cardiovascular outcomes in patients with type 2 diabetes. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 1703-1713.	1.4	12
141	Liver Cirrhosis, Not Antiviral Therapy, Predicts Clinical Outcome in Cohorts with Heterogeneous Hepatitis B Viral Status. <i>Gut and Liver</i> , 2019, 13, 197-205.	1.4	12
142	Clinical Indication of Aspirin Associated With Reduced Risk of Liver Cancer in Chronic Hepatitis B: A Nationwide Cohort Study. <i>American Journal of Gastroenterology</i> , 2022, 117, 758-768.	0.2	12
143	Acute Variceal Hemorrhage in Patients with Liver Cirrhosis: Weekend versus Weekday Admissions. <i>Yonsei Medical Journal</i> , 2012, 53, 318.	0.9	11
144	Sarcopenia assessed using bioimpedance analysis is associated independently with significant liver fibrosis in patients with chronic liver diseases. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 58-65.	0.8	11

#	ARTICLE	IF	CITATIONS
145	Change in the Recurrence Pattern and Predictors over Time after Complete Cure of Hepatocellular Carcinoma. <i>Gut and Liver</i> , 2021, 15, 420-429.	1.4	11
146	Discordance between Liver Biopsy and FibroTest in Assessing Liver Fibrosis in Chronic Hepatitis B. <i>PLoS ONE</i> , 2013, 8, e55759.	1.1	11
147	Normal range of alanine aminotransferase levels for Asian population. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 219-220.	1.4	10
148	Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide-naïve chronic hepatitis B patients in Korea: data from the clinical practice setting in a single-center cohort. <i>Clinical and Molecular Hepatology</i> , 2014, 20, 261.	4.5	10
149	Efficacy of switching from adefovir to tenofovir in chronic hepatitis B patients who exhibit suboptimal responses to adefovir-based combination rescue therapy due to resistance to nucleoside analogues (SATIS study). <i>Clinical and Molecular Hepatology</i> , 2016, 22, 443-449.	4.5	10
150	Predictors of Discordance in the Assessment of Skeletal Muscle Mass between Computed Tomography and Bioimpedance Analysis. <i>Journal of Clinical Medicine</i> , 2019, 8, 322.	1.0	9
151	Hepatocellular Carcinoma Risk According to Regimens for Eradication of Hepatitis C Virus; Interferon or Direct Acting Antivirals. <i>Cancers</i> , 2020, 12, 3414.	1.7	9
152	Evolution of liver fibrosis and steatosis markers in patients with type 2 diabetes after metformin treatment for 2 years. <i>Journal of Diabetes and Its Complications</i> , 2021, 35, 107747.	1.2	9
153	Comparison of the Effects of Telbivudine and Entecavir Treatment on Estimated Glomerular Filtration Rate in Patients with Chronic Hepatitis B. <i>Gut and Liver</i> , 2015, 9, 776.	1.4	9
154	Cost-effectiveness of chronic hepatitis C screening and treatment. <i>Clinical and Molecular Hepatology</i> , 2022, 28, 164-173.	4.5	9
155	Prediction of virologic response to tenofovir mono-rescue therapy for multidrug resistant chronic hepatitis B. <i>Journal of Medical Virology</i> , 2016, 88, 1027-1034.	2.5	8
156	Prognostic factors of sorafenib therapy in hepatocellular carcinoma patients with failure of transarterial chemoembolization. <i>Hepatology International</i> , 2017, 11, 292-299.	1.9	8
157	Transarterial Chemoembolization in Treatment-Naïve and Recurrent Hepatocellular Carcinoma: A Propensity-Matched Outcome Analysis. <i>Digestive Diseases and Sciences</i> , 2019, 64, 3660-3668.	1.1	8
158	Feasibility of dynamic risk assessment for patients with repeated trans-arterial chemoembolization for hepatocellular carcinoma. <i>BMC Cancer</i> , 2019, 19, 363.	1.1	8
159	Validation of risk prediction scores for hepatocellular carcinoma in patients with chronic hepatitis B treated with entecavir or tenofovir. <i>Journal of Viral Hepatitis</i> , 2021, 28, 95-104.	1.0	8
160	Cost-Effectiveness Analysis of Antiviral Therapy for Untreated Minimally Active Chronic Hepatitis B to Prevent Liver Disease Progression. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00299.	1.3	8
161	No influence of hepatic steatosis on the 3-year outcomes of patients with quiescent chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1545-1553.	1.0	8
162	Liver Stiffness-Based Risk Prediction Model for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease. <i>Cancers</i> , 2021, 13, 4567.	1.7	8

#	ARTICLE	IF	CITATIONS
163	Episodic Detectable Viremia Does Not Affect Prognosis in Untreated Compensated Cirrhosis With Serum Hepatitis B Virus DNA &lt;math>\geq 2,000</math> IU/mL. <i>American Journal of Gastroenterology</i> , 2022, 117, 288-294.	0.2	8
164	Combination of Transient Elastography and an Enhanced Liver Fibrosis Test to Assess the Degree of Liver Fibrosis in Patients with Chronic Hepatitis B. <i>Gut and Liver</i> , 2018, 12, 190-200.	1.4	8
165	Daclatasvir Plus Asunaprevir for the Treatment of Patients with Hepatitis C Virus Genotype 1b Infection: Real-World Efficacy, Changes in Liver Stiffness and Fibrosis Markers, and Safety. <i>Gut and Liver</i> , 2018, 12, 324-330.	1.4	8
166	Comparison of FibroScan-Aspartate Aminotransferase (FAST) Score and Other Non-invasive Surrogates in Predicting High-Risk Non-alcoholic Steatohepatitis Criteria. <i>Frontiers in Medicine</i> , 2022, 9, 869190.	1.2	8
167	Liver-Directed Concurrent Chemoradiotherapy versus Sorafenib in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis. <i>Cancers</i> , 2022, 14, 2396.	1.7	8
168	The effect of pharmacological treatment and lifestyle modification in patients with nonalcoholic fatty liver disease: An umbrella review of meta-analyses of randomized controlled trials. <i>Obesity Reviews</i> , 2022, 23, e13464.	3.1	8
169	External Validation of P2/MS and Comparison with Other Simple Non-invasive Indices for Predicting Liver Fibrosis in HBV-Infected Patients. <i>Digestive Diseases and Sciences</i> , 2010, 55, 2636-2643.	1.1	7
170	Pre-S mutations of hepatitis B virus affect genome replication and expression of surface antigens. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 843-850.	1.4	7
171	Clinical Utility of a New Automated Hepatitis C Virus Core Antigen Assay for Prediction of Treatment Response in Patients with Chronic Hepatitis C. <i>Journal of Korean Medical Science</i> , 2016, 31, 1431.	1.1	7
172	Outcome of adefovir add-on lamivudine rescue therapy of up to 5 years in patients with lamivudine-resistant chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 241-247.	1.4	7
173	Switching from tenofovir and nucleoside analogue therapy to tenofovir monotherapy in virologically suppressed chronic hepatitis B patients with antiviral resistance. <i>Journal of Medical Virology</i> , 2018, 90, 497-502.	2.5	7
174	Refractoriness to transarterial chemoembolization in patients with recurrent hepatocellular carcinoma after curative resection. <i>PLoS ONE</i> , 2019, 14, e0214613.	1.1	7
175	A multicentre study of trends in hepatitis B virus-related hepatocellular carcinoma risk over time during long-term entecavir therapy. <i>Journal of Viral Hepatitis</i> , 2020, 27, 1352-1358.	1.0	7
176	Knockdown of Atg7 suppresses Tumorigenesis in a murine model of liver cancer. <i>Translational Oncology</i> , 2021, 14, 101158.	1.7	7
177	Conditional survival estimate in patients with Barcelona Clinic Liver Cancer stage B/C hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy with/without concurrent radiotherapy. <i>Oncotarget</i> , 2017, 8, 79914-79926.	0.8	7
178	Long-term renal safety between patients with chronic hepatitis B receiving tenofovir vs. entecavir therapy: A multicenter study. <i>Journal of Viral Hepatitis</i> , 2022, 29, 289-296.	1.0	7
179	Hepatitis B Virus Serology to Predict Antiviral Response in Chronic Hepatitis B. <i>Digestion</i> , 2011, 84, 29-34.	1.2	6
180	Clinical predictors of silent but substantial liver fibrosis in primary Sjogren's syndrome. <i>Modern Rheumatology</i> , 2016, 26, 576-582.	0.9	6

#	ARTICLE	IF	CITATIONS
181	Association between liver fibrosis and appendicular skeletal muscle mass during antiviral therapy in chronic hepatitis B. <i>Digestive and Liver Disease</i> , 2020, 52, 1338-1345.	0.4	6
182	Entecavir and tenofovir on renal function in patients with hepatitis B virus-related hepatocellular carcinoma. <i>Journal of Viral Hepatitis</i> , 2020, 27, 932-940.	1.0	6
183	Prognostic Value of Alpha-Fetoprotein in Patients Who Achieve a Complete Response to Transarterial Chemoembolization for Hepatocellular Carcinoma. <i>Yonsei Medical Journal</i> , 2021, 62, 12.	0.9	6
184	The cutoff of transient elastography for the evaluation of portal hypertension should be different according to the etiology?. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 91-93.	4.5	6
185	External validation of CAGE and SAGE scores for Asian chronic hepatitis B patients with well-controlled viremia by antivirals. <i>Journal of Viral Hepatitis</i> , 2021, 28, 951-958.	1.0	6
186	Appraisal of Long-Term Outcomes of Liver-Directed Concurrent Chemoradiotherapy for Hepatocellular Carcinoma with Major Portal Vein Invasion. <i>Journal of Hepatocellular Carcinoma</i> , 2020, Volume 7, 403-412.	1.8	6
187	Influence of Besifovir Dipivoxil Maleate Combined with L-Carnitine on Hepatic Steatosis in Patients with Chronic Hepatitis B. <i>Journal of Korean Medical Science</i> , 2020, 35, e104.	1.1	6
188	Novel Liver Stiffness-Based Nomogram for Predicting Hepatocellular Carcinoma Risk in Patients with Chronic Hepatitis B Virus Infection Initiating Antiviral Therapy. <i>Cancers</i> , 2021, 13, 5892.	1.7	6
189	Transarterial Radioembolization for Unresectable Hepatocellular Carcinoma: Real-Life Efficacy and Safety Analysis of Korean Patients. <i>Cancers</i> , 2022, 14, 385.	1.7	6
190	Statin use and risk of progression to liver cirrhosis in chronic hepatitis B independent of conventional risk factors: A nationwide study. <i>Hepatology Communications</i> , 2022, 6, 2455-2464.	2.0	6
191	Non-O1, Non-O139 <i>Vibrio cholerae</i> Septicemia after Acupuncture. <i>The Ewha Medical Journal</i> , 2013, 36, S22.	0.1	5
192	Inter-observer variability of response evaluation criteria for hepatocellular carcinoma treated with chemoembolization. <i>Digestive and Liver Disease</i> , 2015, 47, 682-688.	0.4	5
193	Durability of the virological response after lamivudine discontinuation in lamivudine-resistant patients with a complete virological response after lamivudine and adefovir combination therapy. <i>Journal of Medical Virology</i> , 2017, 89, 85-90.	2.5	5
194	Impact of antiviral therapy on risk prediction model for hepatocellular carcinoma development in patients with chronic hepatitis B. <i>Hepatology Research</i> , 2021, 51, 406-416.	1.8	5
195	Screening, confirmation, and treatment rates of hepatitis C virus infection in a tertiary academic medical center in South Korea. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2479-2485.	1.4	5
196	Long-term effects of entecavir and tenofovir treatment on the fibrotic burden in patients with chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 200-207.	1.4	5
197	Survival Estimates after Stopping Sorafenib in Patients with Hepatocellular Carcinoma: NEXT Score Development and Validation. <i>Gut and Liver</i> , 2017, 11, 693-701.	1.4	5
198	Multicenter Retrospective Risk Assessment of Esophageal Variceal Bleeding in Patients with Cirrhosis: An Acoustic Radiation Force Impulse Elastography-Based Prediction Model. <i>Gut and Liver</i> , 2019, 13, 206-214.	1.4	5

#	ARTICLE	IF	CITATIONS
199	Disease duration and Medsger's severity score are associated with significant liver fibrosis in patients with systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S68-74.	0.4	5
200	Predictive validation of qualitative fibrosis staging in patients with chronic hepatitis B on antiviral therapy. <i>Scientific Reports</i> , 2019, 9, 15628.	1.6	4
201	Fibrosis-matched outcomes between chronic hepatitis B patients with drug-induced virological response and inactive carriers. <i>Liver International</i> , 2019, 39, 81-89.	1.9	4
202	Risk assessment of hepatocellular carcinoma and liver-related events using ultrasonography and transient elastography in patients with chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1362-1372.	1.0	4
203	Prevalence and Risk Factors of Cardiovascular Disease in Patients with Chronic Hepatitis B. <i>Digestive Diseases and Sciences</i> , 2021, , 1.	1.1	4
204	Dynamics of liver stiffness-based risk prediction model during antiviral therapy in patients with chronic hepatitis B. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, 885-893.	0.8	4
205	Hepatocellular Carcinoma Prediction Models for Patients with Chronic Hepatitis B Virus Infection in the Era of Potent Antiviral Therapy. <i>Journal of Liver Cancer</i> , 2018, 18, 87-93.	0.3	4
206	Assessment of fibrotic burden among chronic hepatitis B virus-infected patients with normal transaminase level. <i>Clinical and Molecular Hepatology</i> , 2018, 24, 367-369.	4.5	4
207	Pharmacological Inhibition of Sonic Hedgehog Signaling Suppresses Tumor Development in a Murine Model of Intrahepatic Cholangiocarcinoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13214.	1.8	4
208	Validation of Pre-/Post-TACE-Predict Models among Patients with Hepatocellular Carcinoma Receiving Transarterial Chemoembolization. <i>Cancers</i> , 2022, 14, 67.	1.7	4
209	How to Revitalize the Abdominal Ultrasonography Education Program. <i>Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The</i> , 2019, 73, 66.	0.2	3
210	Direct-Acting Antivirals Improve Treatment Outcomes in Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma Treated with Transarterial Chemoembolization: A Nationwide, Multi-center, Retrospective Cohort Study. <i>Digestive Diseases and Sciences</i> , 2020, 66, 2427-2438.	1.1	3
211	Treatment efficacy by hepatic arterial infusion chemotherapy vs. sorafenib after liver-directed concurrent chemoradiotherapy for advanced hepatocellular carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 3123-3133.	1.2	3
212	Revised Korean Antiviral Guideline Reduces the Hepatitis B-related Hepatocellular Carcinoma Risk in Cirrhotic Patients. <i>Journal of Korean Medical Science</i> , 2021, 36, e105.	1.1	3
213	Transient elastography can be integrated into routine clinical practice for the evaluation of portal hypertension?. <i>Clinical and Molecular Hepatology</i> , 2017, 23, 27-30.	4.5	3
214	Correlation of the grade of hepatic steatosis between controlled attenuation parameter and ultrasound in patients with fatty liver: a multi-center retrospective cohort study. <i>Korean Journal of Internal Medicine</i> , 2020, 35, 1346-1353.	0.7	3
215	Prediction of Esophageal Variceal Bleeding in B-Viral Liver Cirrhosis Using the P2/MS Noninvasive Index Based on Complete Blood Counts. <i>Digestion</i> , 2012, 86, 264-272.	1.2	2
216	Optimal timing of combining sorafenib with locoregional treatments in patients with advanced hepatocellular carcinoma. <i>European Journal of Gastroenterology and Hepatology</i> , 2013, 25, 514-515.	0.8	2

#	ARTICLE	IF	CITATIONS
217	Factors that affect visibility during endoscopic hemostasis for upper GI bleeding: a prospective study. <i>Gastrointestinal Endoscopy</i> , 2015, 81, 1392-1400.	0.5	2
218	Editorial: effect of hepatic steatosis on liver stiffness in patients with chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 333-334.	1.9	2
219	Combined use of rosuvastatin and ezetimibe improves hepatic steatosis in patients with dyslipidemia. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 1538-1544.	0.8	2
220	Establishment and validation of a risk prediction model in patients with hepatocellular carcinoma treated with transarterial radioembolization. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 739-747.	0.8	2
221	Pharmacokinetics and safety of evogliptin in hepatically impaired patients. <i>British Journal of Clinical Pharmacology</i> , 2020, 87, 2757-2766.	1.1	2
222	Clinical relevance of dynamic risk assessment for developing hepatocellular carcinoma during prolonged antiviral therapy. <i>Journal of Hepatology</i> , 2020, 73, 222-223.	1.8	2
223	Predictors of Complete Response in Patients with Hepatocellular Carcinoma Treated with Trans-Arterial Radioembolization. <i>Current Oncology</i> , 2021, 28, 965-977.	0.9	2
224	A Case of Lymphocyte-Rich Hepatocellular Carcinoma in a Patient Who Was Treated for Colon Cancer. <i>Journal of Liver Cancer</i> , 2021, 21, 69-75.	0.3	2
225	The Prognostic Role of On-Treatment Liver Stiffness for Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 467-476.	1.8	2
226	Autoimmune Hepatic Failure Following Acute Hepatitis A is Accompanied by Inflammatory Conversion of Regulatory T Cells. <i>Yonsei Medical Journal</i> , 2020, 61, 100.	0.9	2
227	Clinical significance of hepatosplenic thrombosis in vaccine-induced immune thrombotic thrombocytopenia after ChAdOx1 nCoV-19 vaccination. <i>International Journal of Infectious Diseases</i> , 2022, 116, 114-121.	1.5	2
228	Comparable Efficacy Between Ongoing Versus Initiation of Antiviral Therapy at Treatment for HBV-related Hepatocellular Carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1877-1880.e3.	2.4	2
229	Cost-effectiveness of antiviral therapy in untreated compensated cirrhosis patient with serum HBV DNA level <math>\leq 2000\text{ IU/mL}</math>. <i>Hepatology International</i> , 2022, 16, 294-305.	1.9	2
230	Reply to "The problem of the most appropriate curative treatment for hepatocellular carcinoma. When to embolize? When to operate?" <i>Journal of Hepatology</i> , 2015, 63, 281-282.	1.8	1
231	The remaining challenges of HCV treatment in the direct-acting antivirals era. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 1891-1892.	1.4	1
232	Letter to the Editor: Re: Tenofovir Versus Entecavir on Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma After Surgical Resection. <i>Hepatology</i> , 2021, 73, 466-466.	3.6	1
233	Association Between Curative Treatment after Transarterial Radioembolization and Better Survival Outcomes in Patients with Hepatocellular Carcinoma. <i>Cancer Investigation</i> , 2021, 39, 274-283.	0.6	1
234	Predictors of Sarcopenia in an Obese Asian Population. <i>Nutrition and Cancer</i> , 2022, 74, 505-514.	0.9	1

#	ARTICLE	IF	CITATIONS
235	How does low-level viremia affect the prognosis of patients with chronic hepatitis B?. <i>Clinical and Molecular Hepatology</i> , 2020, 26, 376-377.	4.5	1
236	Proposal of a New Risk Score for Patients Treated with Transarterial Chemoembolization due to Recurrent Hepatocellular Carcinoma after Curative Resection: A Multicenter Study. <i>Gut and Liver</i> , 2020, 14, 477-485.	1.4	1
237	External Validation of the FSAC Model Using On-Therapy Changes in Noninvasive Fibrosis Markers in Patients with Chronic Hepatitis B: A Multicenter Study. <i>Cancers</i> , 2022, 14, 711.	1.7	1
238	Liver-directed concurrent chemoradiotherapy versus sorafenib in hepatocellular carcinoma with portal vein tumor thrombus.. <i>Journal of Clinical Oncology</i> , 2022, 40, 424-424.	0.8	1
239	Validation of PH and Varices Risk Scores for Prediction of High-Risk Esophageal Varix and Bleeding in Patients with B-Viral Cirrhosis. <i>Diagnostics</i> , 2022, 12, 441.	1.3	1
240	Effects of Hepatic Impairment on the Pharmacokinetic Profile and Safety of Lobbeglitazone. <i>Clinical Pharmacology in Drug Development</i> , 2022, 11, 576-584.	0.8	1
241	Fibrotic burden during antiviral therapy for chronic hepatitis B, not <scp>ALT</scp> level, independently predicts liver cancer risk. <i>Liver International</i> , 2022, 42, 1902-1906.	1.9	1
242	Reply to "Response assessment for HCC patients treated with repeated TACE: The optimal time-point is still an open issue". <i>Journal of Hepatology</i> , 2015, 63, 1532.	1.8	0
243	IDDF2018-ABS-0028"Risk assessment in patients treated with tace due to recurred hepatocellular carcinoma after curative resection. , 2018, , .		0
244	IDDF2018-ABS-0027"Influence of hepatic steatosis on the treatment outcomes of entecavir and tenofovir in patients with chronic hepatitis B. , 2018, , .		0
245	Reply to: "Comparison of risk of hepatocellular carcinoma between tenofovir and entecavir: One direction or no direction". <i>Journal of Hepatology</i> , 2019, 71, 847-848.	1.8	0
246	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 264-265.	2.4	0
247	Reply to: "Comment on " A multi-center study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in the Republic of Korea". <i>Journal of Hepatology</i> , 2020, 72, 198-199.	1.8	0
248	Advanced Stage Hepatocellular Carcinoma Successfully Treated with Liver-directed Concurrent Chemoradiotherapy and Sequential Transarterial Radio-embolization. <i>Journal of Liver Cancer</i> , 2021, 21, 97-103.	0.3	0
249	A Case of Successful Treatments of Venous Leg Ulcers in Secondary Antiphospholipid Syndrome. <i>The Journal of the Korean Rheumatism Association</i> , 2007, 14, 71.	0.1	0
250	Efficacy and safety of localized concurrent chemoradiation therapy and sorafenib sequential therapy in advanced hepatocellular carcinoma: A prospective phase II trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, e15678-e15678.	0.8	0
251	Dickkopf-1 promotes angiogenesis by upregulating VEGF receptor 2-mediated mTOR/p70S6K signaling in hepatocellular carcinoma. <i>American Journal of Cancer Research</i> , 2021, 11, 4788-4806.	1.4	0
252	Laparoscopic liver resection versus percutaneous radiofrequency ablation for single small hepatocellular carcinoma (≥ 3 cm): Optimal indication based on the tumor size and the level of PIVKA-II. <i>Annals of Hepato-biliary-pancreatic Surgery</i> , 2022, 26, S92-S92.	0.1	0